Lilly to lay off 8 percent of employees in bid to cut costs

Go back to Lilly to lay off 8 percent of employees in bid to cut costs

Eli Lilly & Co. (LLY) Presents Clinical Evidence for CYRAMZA (ramucirumab) with Phase 3 RANGE Data Demonstrating Superior Progression-Free Survival in Advanced or Metastatic Urothelial Cancer

September 11, 2017 5:57 AM EDT

At the European Society for Medical Oncology (ESMO) 2017 Congress today, Phase 3 RANGE data from Eli Lilly and Company (NYSE: LLY) were presented in the Presidential Symposium (abstract#: LBA4_PR). These are the first detailed results from the global, randomized, double-blinded, placebo-controlled RANGE study of CYRAMZA® (ramucirumab), in combination with docetaxel, in patients with advanced or metastatic urothelial carcinoma whose disease progressed on or after platinum-based chemotherapy. The data showed a statistically significant improvement in progression-free survival (PFS) in patients treated with ramucirumab plus docetaxel when compared to those who received placebo plus docetaxel, with a... More

Eli Lilly (LLY) PT Raised to $105 at Piper Jaffray Amid Streamlining

September 8, 2017 6:27 AM EDT

Piper Jaffray raised its price target on Eli Lilly (NYSE: LLY) to $105.00 (from $103.00) while maintaining a Overweight rating.

Analyst Richard Purkiss said the announced streamlining boosts the growth outlook.

... More